News
-
ADmit Therapeutics receives accreditation from the College of American Pathologists
Barcelona – November 14, 2024. The Committee on Accreditation of the College of American Pathologists (CAP) has granted accreditation to ADmit Therapeutics, Barcelona, based on the results of the recent on-site inspection conducted as part of CAP’s Accreditation Programmes. The director of the laboratory, Dr. Marta Blanch was notified of this national recognition and congratulated…
-
ADmit Therapeutics extends the scope of its ISO13485
ADmit Therapeutics announces that it has successfully passed the annual external audit, demonstrating that the medical device quality management system and its effectiveness are adequately maintained. We are pleased to share that, in our tireless effort to pursue excellence in quality, the scope of our ISO13485:2016 certification has been expanded to include the manufacturing of…
-
ADmit Therapeutics has been selected to join StartUp Health’s Alzheimer’s Moonshot Community.
21 of May, 2024 ADmit Therapeutics, has been selected to be part of the prestigious Alzheimer’s Moonshot Community driven by StartUp Health. This initiative brings together startups, investors and organisations focused on accelerating transformative solutions for the prevention, detection and treatment of Alzheimer’s disease. Through this inclusion, ADmit Therapeutics will have access to a global…
-
ADmit incorporates Ferran Prat as Chairman of its Board of Directors.
He has more than 30 years of experience in the Life Sciences industry, mainly in Diagnostics and Pharma. He has held positions as CEO, Corporate Vice President Marketing, Strategic Alliances and Business Development, as well as Chief Commercial Officer and Chief Operating Officer in several companies, such as VITRO Group, Werfen, LETI Pharma, DAKO (an…
-
ADmit Therapeutics participated last week in the ADDF Investigators Day and AD/PD 2024 congress held in Lisbon.
Our CEO participated in the Alzheimer’s Drug Discovery Foundation Investigators Day to explain ADmit’s technology based on novel biomarkers in blood for the prognosis of Alzheimer’s disease. In addition, two posters were presented during the AD/PD 2024 congress in Lisbon (Poster Shift1 0299: Analytical validation of blood mitochondrial methylcytosines for the prognosis of AD dementia…
